Zanzalintinib
- Generic Name
- Zanzalintinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C29H25FN4O5
- CAS Number
- 2367004-54-2
- Unique Ingredient Identifier
- KC2JC2ZA04
- Associated Conditions
- -
- Associated Therapies
- -
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
- Conditions
- Interventions
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Anwaar Saeed
- Target Recruit Count
- 40
- Registration Number
- NCT06698250
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 29
- Registration Number
- NCT06571734
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 32
- Registration Number
- NCT06568562
- Locations
- 🇺🇸
Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States
Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 140
- Registration Number
- NCT06191796
- Locations
- 🇺🇸
Exelixis Site #8, Los Angeles, California, United States
🇺🇸Exelixis Site #9, Miami, Florida, United States
🇺🇸Exelixis Clinical Site #1, Orlando, Florida, United States
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 500
- Registration Number
- NCT06082167
- Locations
- 🇧🇷
Exelixis Clinical Site #68, Passo Fundo, Rio Grande Do Sul, Brazil
🇺🇸Exelixis Clinical Site #19, Chicago, Illinois, United States
🇺🇸Exelixis Clinical Site #62, Des Moines, Iowa, United States
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 291
- Registration Number
- NCT05678673
- Locations
- 🇺🇸
Exelixis Clinical Site #164, Newport Beach, California, United States
🇺🇸Exelixis Clinical Site #162, San Francisco, California, United States
🇺🇸Exelixis Clinical Site #163, Aurora, Colorado, United States
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 874
- Registration Number
- NCT05425940
- Locations
- 🇺🇸
Exelixis Clinical Site #77, Los Angeles, California, United States
🇺🇸Exelixis Clinical Site #106, Philadelphia, Pennsylvania, United States
🇺🇸Exelixis Clinical Site #103, Pittsburgh, Pennsylvania, United States
Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 1274
- Registration Number
- NCT05176483
- Locations
- 🇺🇸
Exelixis Clinical Site #32, Pittsburgh, Pennsylvania, United States
🇺🇸Exelixis Clinical Site #24, Pittsburgh, Pennsylvania, United States
🇺🇸Exelixis Clinical Site #89, Dallas, Texas, United States
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 325
- Registration Number
- NCT03845166
- Locations
- 🇺🇸
Exelixis Clinical Site #84, Los Angeles, California, United States
🇺🇸Exelixis Clinical Site #71, Stanford, California, United States
🇺🇸Exelixis Clinical Site #85, Bronx, New York, United States
A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
- Conditions
- Interventions
- Drug: AtezolizumabDrug: DocetaxelDrug: RO6958688Drug: CPI-444Drug: LinagliptinDrug: Sacituzumab GovitecanDrug: BevacizumabDrug: CamonsertibDrug: CobimetinibDrug: IpatasertibDrug: PemetrexedDrug: EvolocumabDrug: TiragolumabOther: RadiationDrug: TocilizumabDrug: CarboplatinDrug: GemcitabineDrug: XL092
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 675
- Registration Number
- NCT03337698
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei City, Taiwan
🇪🇸Hospital Clinico Universitario de Valencia, Valencia, Spain
🇨🇳National Cheng Kung University Hospital; Gasterointestinal, Tainan City, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.